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Abstract
Objective. To describe the baseline characteristics, biologic DMARD (bDMARD) response and drug survival of
axial SpA (axSpA) patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
(BSRBR-AS) according to radiographic status.
Methods. The BSRBR-AS is a national prospective cohort including axSpA participants classified according to the
Assessment of SpondyloArthritis international Society criteria. In this analysis, baseline data of patients starting
bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDASs) for low disease status, clinical-
ly important improvement (CII) and major improvement (MI) at 1 year were used to assess treatment response. Cox
proportional hazards analysis was performed after adjusting for clinically relevant confounders.
Results. A total of 1145 axSpA patients were included. Higher male prevalence, older age and longer disease dur-
ation were seen in the radiographic axSpA (r-axSpA) subgroup. Based on a complete case analysis (290 patients),
two-thirds of patients achieved an ASDAS low disease state at 1 year regardless of radiographic status [non-
radiographic axSpA (nr-axSpA) 64.2% vs r-axSpA 66.1]. No statistically significant differences were seen between
the subgroups in attaining ASDAS CII (nr-axSpA 50.7% vs r-axSpA 44.7%) or MI (nr-axSpA 20% vs r-axSpA
18.7%). Drug survival probability curves were similar for both subgroups and the hazard ratio for nr-axSpA/axSpA
was 0.94 (95% CI 0.69, 1.28) when adjusted for sex, age, baseline ASDAS with CRP, smoking status, disease dur-
ation, HLA-B27 and prescribed biologic.
Conclusions. Although there appeared to be some differences in the baseline characteristics when exploring this
cohort according to radiographic status, which are likely related to the natural history of the disease, the level of
biologic response and drug survival was comparable between nr-axSpA and r-axSpA.
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Introduction
AS is the established phenotype of axial SpA (axSpA),
an inflammatory condition affecting primarily the enthesis
and axial skeleton, with a usually earlier, more heteroge-
neous phenotype classified as non-radiographic axSpA
(nr-axSpA) [1]. Nr-axSpA has caused much controversy
in recent years, with some arguing that it represents an
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. This is the largest prospective study comparing nr-axSpA and r-axSpA showing similar baseline characteristics.
. Drug response evaluated by ASDAS and drug survival was comparable between nr-axSpA and r-axSpA.
. These results add evidence that similar treatment strategies should be followed in nr-axSpA and r-axSpA.
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earlier disease stage that might progress to AS, called
radiographic axSpA (r-axSpA), while others believe that
it represents a separate entity that should be treated
distinctively. Following the introduction of the
Assessment of Spondyloarthritis international Society
(ASAS) classification criteria [2], the rheumatology com-
munity has an increased awareness of the diagnostic
issues in axSpA if such criteria are misused, particularly
in the non-radiographic patient subgroup. Yet, despite
growing evidence that nr-axSpA and r-axSpA show a
comparable burden of disease [3], different treatment
strategies are still suggested [4].
Biologic DMARDs (bDMARDs) have completely
changed the outlook for patients with axSpA, with sig-
nificant numbers achieving long-term remission or low
disease activity over time. There are ample data on the
efficacy of TNF inhibitors (TNFis) in nr-axSpA coming
from phase III trials [5–8]. However, only a handful of tri-
als (RAPID-axSpA and ESTHER trial) [5, 6] and a post-
hoc analysis of the INFAST study looked at the whole
axSpA spectrum [9], including patients with both non-
radiographic and radiographic disease and showing
comparable results across both subgroups. Real-life
data are even more scarce, with only a couple of small
studies [10, 11] and two larger cohorts, the DANBIO
register and the Swiss Clinical Quality Management
(SCQM) Cohort [12, 13] published to date.
The British Society for Rheumatology Biologics
Registry for Ankylosing Spondylitis (BSRBR-AS) [14]
holds a large volume of data comprising both patient
subgroups (AS and nr-axSpA), with significant numbers
exposed to biologic agents. Based on the hypothesis
that both subgroups are part of the same disease con-
tinuum and hence have a comparable response to treat-
ment, the aims of this study were to explore the
baseline characteristics of the two populations in the
BSRBR-AS cohort and to evaluate the level of disease
control according to the Ankylosing Spondylitis Disease
Activity Score (ASDAS) and the drug survival of the first
bDMARD at 1 year.
Methods
Longitudinal data from the prospective BSRBR-AS co-
hort study were used for this analysis. The BSRBR-AS
cohort has been previously described [14]. Briefly, it
includes axSpA patients meeting the ASAS criteria or
the modified New York criteria for AS from 83 rheuma-
tology centres across the UK recruited between
December 2012 and December 2017. To enter the regis-
try, patients with axSpA were required to be biologic
naı̈ve and were subsequently included in the ‘biologic
cohort’ if starting a bDMARD (comprised only of TNFis
at the time, mainly originator adalimumab, etanercept,
infliximab or certolizumab pegol) or remained in the
‘non-biologic cohort’ otherwise. Clinical data and
patient-reported questionnaires were retrieved at 3, 6
and 12 months and annually thereafter in the biologic
cohort.
For this analysis, we included all axSpA patients start-
ing a bDMARD who were categorized in the r-axSpA
(participants with documented X-ray evidence of sacroi-
liitis as per the modified New York criteria in their medic-
al notes) or the nr-axSpA subgroup (no such evidence).
The primary outcome of our study was response to
bDMARDs at 1 year follow-up defined as 12 months (S.D.
4) from the baseline visit and drug survival of the first ini-
tiated bDMARD. Treatment response was assessed with
the ASDAS-CRP (calculated using collected CRP values
and relevant patient-reported outcomes items). Where
CRP was normal or <0.2 mg/dl, the value of 0.2 was
used in the formula as recommended by Machado et al.
[15]. Different scenarios were explored: patients achiev-
ing a low disease state (ASDAS <2.1), an ASDAS reduc-
tion of 2.0 [major improvement (MI)] or an ASDAS
reduction of 1.1 [clinically important improvement (CII)].
Analysis was restricted to patients with an ASDAS avail-
able at baseline. We performed an additional analysis
classifying patients as responders if they achieved an
ASDAS low disease state or showed an ASDAS MI or
CII. Where the 12 month assessment was missing but
individuals remained on a drug, they were considered as
responders if they demonstrated a response at
6 months.
Statistical analysis
Baseline characteristics were compared between both
subgroups (nr- vs r-axSpA). Student’s t- or Mann–
Whitney U test for continuous variables and chi-squared
test for categorical variables were used. The proportion
of patients attaining an ASDAS low disease state, MI or
CII were compared when the ASDAS was available for
both the baseline and 1 year time point (complete case
analysis).
Drug survival was defined as the time from initiation to
the end of the first bDMARD (switches to biosimilars
were not considered a treatment discontinuation) or to
the last available follow-up date (censoring) and were
explored using Kaplan–Meier plots and the log-rank test.
Cox proportional hazards analysis was performed after
adjusting for clinically relevant confounders (sex, age,
baseline ASDAS, smoking status, disease duration, HLA-
B27 and prescribed biologic) to assess the possible im-
pact of radiographic status on response to bDMARD
therapy. The proportional hazards assumption was not
violated after analytical and graphical testing. All analysis
was conducted using Stata version 16.1 (StataCorp,
College Station, TX, USA).
Results
Baseline characteristics were available in 1145 patients
(Table 1), of whom 727 (63.5%) had radiographic sacroi-
liitis and were classified as r-axSpA. Regarding the nr-
axSpA population, 90% (n¼ 378) had a positive SIJ
MRI, as per the standardized ASAS definition, while only
40 patients were classified according to the clinical arm
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[2]. Compared with nr-axSpA, those with r-axSpA were
more likely to be male, older and had longer disease
duration. Uveitis was more frequently reported in the r-
axSpA population, who also were more likely to be ever-
smokers. Baseline BASFI and CRP levels were higher in
the r-axSpA subgroup. When exploring comorbidities,
these were statistically more frequent in the r-axSpA
subgroup, with the main difference seen in the preva-
lence of hypertension (see supplementary material 1,
available at Rheumatology online).
Disease activity and treatment response
Disease activity measures and functional index at base-
line and the 1 year time point are presented in supple-
mentary material 2, available at Rheumatology online.
Follow-up ASDAS was available in only 290 patients, so
we explored the baseline characteristics of patients with
missing values and found no significant differences in
baseline ASDAS-CRP, concomitant NSAID or TNF drug
used (supplementary material 3, available at
Rheumatology online). Of note, patients with missing val-
ues were significantly younger and had a shorter disease
duration. Overall, two-thirds of the patients with available
follow-up ASDAS data achieved a low disease state
(ASDAS <2.1) at 1 year regardless of radiographic status
[nr-axSpA 64.2% vs r-axSpA 66.1%; difference 1.9%
(95% CI 13.7, 9.8)]. Further, no significant differences
were seen between the subgroups in attaining ASDAS
CII [nr-axSpA 50.7% vs r-axSpA 44.7%; difference 6.0%
(95% CI 7.8, 19.8)] or MI [nr-axSpA 20% vs r-axSpA
18.7%; difference 1.3% (95% CI 9.7, 12.3)].
Additionally, no differences were seen between the r-
and nr-axSpA subgroups when patients were classified
as responders (ASDAS low disease state, CII or MI) or
non-responders [nr-axSpA 76.2% vs r-axSpA 72.6 res-
ponders; difference 3.6% (95% CI 5.2, 12.3)].
Drug survival
The median follow-up was 24 months (IQR 12–39). The
first bDMARD stop time was available for 1122 patients.
A total of 387 patients (33.8%) stopped their first
bDMARD due to adverse events (nr-axSpA 34%, r-
axSpA 37%) and lack of efficacy (nr-axSpA 35%, r-
axSpA 30%) as the most frequent reasons for discon-
tinuation, with no statistically significant differences
found between both subgroups. Kaplan–Meier curves
were similar for both subgroups (log-rank test P¼ 0.12),
with a median survival time of 39.5 months (95% CI
33.7, 48.1) in the nr-axSpA subgroup vs 41.4 months
(95% CI 38.5, 49.4) in the r-axSpA subgroup (Fig. 1). In
the multivariable analysis, the hazard ratio for nr-axSpA/
axSpA was 0.94 (95% CI 0.69, 1.28) when adjusted for
sex, age, baseline ASDAS-CRP, smoking status, disease
duration, HLA-B27 status and prescribed biologic.
TABLE 1 Baseline characteristics of patients of the BSRBR-AS cohort according to radiographic status
Variables Level nr-axSpA (n 5 418) r-axSpA (n 5 727) P-value
Age, mean (S.D.), years 39.7 (12.3) 46.1 (13.4) <0.001
Sex, n (%) Male 239 (57) 529 (73) <0.001
Symptom duration, mean (S.D.), years 11.3 (10.9) 16.7 (12.9) <0.001
Diagnostic delay, median (IQR), years 3.0 (1.0–10.0) 3.0 (0.0–11.0) 0.83
HLA-B27 (missing¼ 325) 227 (73) 387 (76) 0.40
Inflammatory back pain, n (%) 405 (97) 697 (97) 0.40
Uveitis, n (%) 92 (22) 205 (30) 0.003
Crohn’s/colitis, n (%) 55 (13) 113 (17) 0.11
Psoriasis, n (%) 79 (19) 115 (17) 0.43
BMI, mean (S.D.) 27.5 (5.6) 28.2 (5.8) 0.10
Comorbidity count, mean (S.D.) 0.6 (0.9) 0.7 (1.0) 0.016
Smoking status, n (%) Never smoked 148 (43) 218 (38) 0.040
Ex-smoker 96 (28) 207 (36)
Current smoker 100 (29) 154 (27)
CRP, median (IQR), mg/dL 0.5 (0.1–1.3) 0.9 (0.3–2.5) <0.001
BASDAI, median (IQR) 6.7 (5.3–7.8) 6.5 (5.0–7.7) 0.12
BASFI, median (IQR) 5.9 (4.2–7.8) 6.5 (4.4–8.3) 0.043
BAS-G, mean (S.D.) 7.0 (2.0) 6.8 (2.0) 0.056
ASDAS-CRP, mean (S.D.) 2.8 (0.8) 2.8 (0.9) 0.32
ASQOL, median (IQR) 13.0 (9.0–16.0) 13.0 (9.0–15.5) 0.29
Concomitant NSAID use, n (%) 311 (75) 560 (77) 0.43
Biologic (to start), n (%) Adalimumab 238 (57) 436 (60) 0.20
Etanercept 131 (31) 220 (30)
Certolizumab 35 (8) 47 (6)
Golimumab 5 (1) 12 (2)
Secukinumab 7 (2) 10 (1)
Infliximab 2 (<1) 2 (<1)
ASQOL: Ankylosing Spondylitis Quality of Life questionnaire.
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Interaction terms with gender and HLA-B27 were added
into the model and did not show significant differences.
When subdividing the nr-axSpA population into those
fulfilling the ASAS imaging or clinical criteria, survival
curves were similar for the three subgroups (supplemen-
tary material 4, available at Rheumatology online).
Discussion
Publication of the ASAS classification criteria led to con-
siderable debate over the last decade as to whether
both nr-axSpA and r-axSpA should be considered the
same entity. Incidentally, the ASAS criteria were never
created to separate, but to encompass the whole axSpA
continuum, facilitating the identification of homogeneous
cohorts in clinical trials. In our analysis of real-world
data from a prospective multicentre cohort, baseline
demographic and clinical characteristics were broadly
similar between nr-axSpA and r-axSpA (AS). Further, the
level of bDMARD response according to the ASDAS was
comparable at 1 year between subgroups, as was the
survival time of the first bDMARD, even in the adjusted
multivariable analysis. Baseline characteristics of our co-
hort were similar to previously published reports, al-
though some particularities are worth mentioning. In our
study, HLA-B27 prevalence was similar between nr- and
r-axSpA, as shown in the SCQM cohort, while r-axSpA
patients from the DANBIO study had a higher prevalence
of positive HLA-B27 [12, 13]. There is a rationale to
assuming that nr- and r-axSpA have the same genetic
background as part of the whole axSpA continuum. The
differences with the Danish registry might be explained
by the heterogeneity of the included patients, as recruit-
ment started in 2000, predating the publication of the
ASAS criteria, which led to the cohort being classified
retrospectively for the analysis. In the BSRBR-AS cohort,
r-axSpA patients are more frequently male than nr-
axSpA patients and this is in line with published litera-
ture [3]. In addition, CRP levels and smoking history
were different between subgroups and might explain a
higher likelihood of progressing to r-axSpA, as these
have been postulated as radiographic progression fac-
tors [16]. The higher radiographic damage of r-axSpA
might relate to higher BASMI and BASFI scores found in
this subgroup as part of the natural history of axSpA.
Moreover, comorbidity count was statistically higher in
patients with r-axSpA, mainly because of the prevalence
of hypertension. Older age and longer disease duration
in the r-axSpA subgroup might explain these findings
[17].
We centred our analysis on the ASDAS response, as
this has been shown to have good discriminatory power
in both AS (r-axSpA) and nr-axSpA [18]. Similar to our
real-world data, a recent clinical trial including patients
with nr-axSpA and r-axSpA treated with certolizumab
achieved the same treatment response at week 48
measured by ASDAS [19]. When exploring the available
evidence in observational cohorts, the 1 year treatment
response as per the ASDAS was higher in the r-axSpA
subgroup in the SCQM cohort, although this was not
statistically significant [13]. In the DANBIO study, the
ASDAS response was similar between both subgroups,
although this was evaluated at the 3 and 6 month time
points. Differences in drug survival have been explored
in a few cohorts [10, 12, 20]. Overall, all reports show
similar treatment adherence in nr-axSpA and r-axSpA as
outlined in our study. Interestingly, a small retrospective
study from Italy did show lower drug survival in nr-
axSpA [20] and poorer adherence in patients with nr-
axSpA was seen in the DANBIO cohort [12], although
this was not confirmed in the multivariate analysis. Most
patients were classified as nr-axSpA due to a positive
SIJ MRI (ASAS imaging arm), so conclusions on drug
survival similarities between the clinical and imaging
arms should be interpreted with caution.
To our knowledge, this is the largest prospective co-
hort study comparing drug response and baseline char-
acteristics between nr-axSpA and r-axSpA. Another
strength is the fact that the study inclusion criteria were
based on fulfilment of the ASAS classification criteria as
opposed to being retrospectively adjudicated, ensuring
the homogeneity of the study population. A limitation of
our study is mainly the amount of missing data at the
1 year time point. This issue was addressed by analysing
excluded patients and finding that there were no differ-
ences in baseline disease activity or treatment used. The
excluded patients were younger and had a shorter dis-
ease duration, suggesting that they were doing well,
which might justify why they did not attend follow-up.
An additional analysis using a 6 month assessment if
they stayed on a bDMARD increased the sample to 407,
showing the same proportion of responders. Also, statis-
tical power was adequate (0.89) with this sample size at
a¼ 0.05 to find a 20% difference between subgroups. In
addition, we performed the drug survival analysis with
most of the population (1122 patients), confirming the
hypothesis that there are no differences between sub-
groups. Another limitation is the absence of regression
analysis comparing the ASDAS response between
FIG. 1 Kaplan–Meier survival curves of nr-axSpA vs r-
axSpA
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subgroups, as this overlapped with a similar study in
this cohort looking at predictors of TNFi response in
axSpA at the first follow-up (10 weeks–9 months) [21]. In
that analysis, disease criteria were not associated with a
lack of response, supporting our results. Moreover, it is
well known that SIJ assessment has limited reliability,
thus misclassification of nr/r-axSpA [22] may have
occurred in some cases, although this cannot be con-
firmed in the absence of CT or MRI of all patients.
However, this study reflects real-life practice whereby
clinicians have to routinely consider this possibility.
In conclusion, nr-axSpA and r-axSpA present with
similar baseline characteristics in a large multicentre co-
hort and achieve the same level of response to
bDMARDs with analogous drug survival. These results
support a unique treatment strategy for axSpA and en-
courage future clinical trial design to encompass the
whole spectrum of axSpA rather than address nr-axSpA
and r-axSpA as independent diseases.
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